This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.

Overactive Bladder Clinical Trial

— BTX0621  

Official title:

Safety and Efficacy Study of Intradetrusor Injections of Botox® for the Treatment of Urinary Incontinence Secondary to Benign Prostatic Obstruction (BTX0621)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00479596
• Other study ID #: BTX0621
• Status: Recruiting
• Phase: Phase 2/Phase 3
• First received: May 25, 2007
• Last updated: May 29, 2007
• Start date: January 2007
• Est. completion date: May 2007

Study information

• Verified date: January 2007
• Source: Urological Sciences Research Foundation
• Contact: Leonard S Marks, M.D.
• Phone: (310) 838-6347
• Email: lsmarks[@]ucla.edu
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The current study will investigate the comparative efficacy, safety and patient satisfaction of intradetrusor injections BOTOX® injections (200U) versus placebo (saline) injections in the treatment of OAB secondary to benign prostatic obstruction (BPO).

Description:

Overactive bladder is a common problem that follows chronic prostatic bladder outlet obstruction and is part of the benign prostatic hyperplasia syndrome (BPH) in men. Unfortunately, it does not often resolve after treatment (TURP, etc) of the obstruction from enlarged prostate gland. Patients with obstructive BPH typically commence treatment with alpha-blockers or anticholinergic agents; the former being used to treat enlarged prostate medically, and the latter to treat overactive bladder symptoms. However, as mentioned, anticholinergics cause many intolerable side effects leading to discontinuation in many patients. Furthermore this class of drug is still considered a relative contraindication in this population by some clinicians. Therefore other modalities need to be studied in these men.

Based on numerous studies in overactive bladder (OAB), we hypothesize that these patients will experience significant improvement (particularly if their symptoms of urgency and frequency) without significant side effects from intradetrusor injections of BOTOX® even though they have were refractory to systemic anticholinergics.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: May 2007
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 40 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Male between 40 and 90 years of age.

2. Clinical signs and symptoms of frequency and urgency

3. Urodynamic history consistent with OAB that developed in conjunction with Benign Prostate Obstruction and that persists for at least 3 months post TURP or PVP, or other obstruction relieving procedure.

4. OAB inadequately controlled with anticholinergic medications

5. Qmax >12mL/s with a voided volume of >125mL.

6. IPSS >12, with IPSS QoL >3 at study Visit 1.

7. Willing to use clean intermittent catheterization (CIC) to empty the bladder or is willing to have an indwelling catheter, if necessary following study treatment.

Exclusion Criteria:

1. Known history of interstitial cystitis, uninvestigated hematuria, bladder outlet obstruction due to vesical neck contracture, mullerian duct cysts, urethral obstruction due to stricture/valves/sclerosis of urethral tumor, radiation cystitis, genitourinary tuberculosis, bladder calculi, or detrusor-sphincter dyssynergia.

2. Current indwelling catheter, or removal of chronic catheter <1 month prior to study entry.

3. Non-compliance with wash-out periods for prohibited medications/therapies

4. Evidence of Urinary Tract Infection according to local standard of care.

5. History of prostate cancer.

6. Serum PSA of >10ng/mL. [NOTE: Subjects with serum PSA concentrations >4 and <10 must have prostate cancer excluded according to the local standard of care.]

7. 24 hour total volume voided >3000 mL of urine

8. Medical condition that may increase their risk of exposure to botulinum toxin including diagnosed Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis or any other disease that might interfere with neuromuscular function.

9. Allergy or sensitivity to any component of BOTOX®

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Overactive Bladder
• Urinary Bladder, Overactive

Intervention

Drug:
• Botox

Locations

Country	Name	City	State
United States	Urological Sciences Research Foundation	Culver City	California

Sponsors (2)

Lead Sponsor	Collaborator
Urological Sciences Research Foundation	Allergan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and efficacy of BOTOX? to placebo (saline) in the treatment of OAB secondary to BPO.		6 months post injection
Secondary	Patient satisfaction to intradetrussor injection of Botox versus placebo.		6 months post injection

External Links

•   Link